← back to search

Amrita Desai

Oregon Health & Science University · US
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include HER2/EGFR in Cancer Research, Lung Cancer Treatments and Mutations, Lymphoma Diagnosis and Treatment, and Monoclonal and Polyclonal Antibodies Research.
h-index
21
citations
3,211
works
130
NIH funding
primary concept
email

Recent publications

Long‐term outcomes of patients with conjunctival extranodal marginal zone lymphoma
American Journal of Hematology 2022cited by 11position: middledoi
Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation
American Journal of Hematology 2019cited by 36position: middledoi
Maintenance rituximab or observation after frontline treatment with bendamustine‐rituximab for follicular lymphoma
British Journal of Haematology 2018cited by 51position: middledoi
Frontline brentuximab vedotin in breast implant‐associated anaplastic large‐cell lymphoma
Clinical Case Reports 2018cited by 38position: middledoi
Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab
Clinical Lung Cancer 2017cited by 65position: middledoi
Phenotype analysis and clinical management in a large family with a novel truncating mutation in RASGRP2, the CalDAG‐GEFI encoding gene
Research and Practice in Thrombosis and Haemostasis 2017cited by 21position: firstdoi
Long-term course of patients with primary ocular adnexal MALT lymphoma: a large single-institution cohort study
Blood 2016cited by 79position: firstdoi
In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response
Breast Cancer Research and Treatment 2015cited by 64position: middledoi
PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.
PubMed 2013cited by 102position: middle
Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer
Molecular Cancer Therapeutics 2013cited by 68position: middledoi
Antiestrogen Fulvestrant Enhances the Antiproliferative Effects of Epidermal Growth Factor Receptor Inhibitors in Human Non–Small-Cell Lung Cancer
Journal of Thoracic Oncology 2013cited by 64position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Dennis J. Slamon · APLA Health4 papers (2013–2015)Izidore S. Lossos · University of Miami4 papers (2016–2022)Jennifer R. Chapman · University of Miami4 papers (2016–2022)Dylan Conklin · APLA Health3 papers (2013–2015)Richard S. Finn · United States Olympic & Paralympic Committee3 papers (2013–2015)Juan Pablo Alderuccio · University of Miami3 papers (2018–2022)Francisco Vega · The University of Texas MD Anderson Cancer Center3 papers (2016–2019)Arnold M. Markoe · University of Miami2 papers (2016–2022)Neil A. O’Brien · APLA Health2 papers (2013–2015)Ondrej Kalous · University of California, Los Angeles2 papers (2013–2015)Wei Zhao · University of Nottingham Ningbo China2 papers (2019–2022)Isildinha M. Reis · University of Miami2 papers (2019–2022)Judy Dering · University of California, Los Angeles2 papers (2013–2015)Lee Anderson · Broad Institute2 papers (2013–2015)Marie‐Christine Alessi · Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement1 papers (2017–2017)Erik L. Kimble · Fred Hutch Cancer Center1 papers (2019–2019)Wylie Hosmer · Hartford Hospital1 papers (2013–2013)Mikhail Akimov · Moscow State University of Printing Arts1 papers (2013–2013)Alan T. Nurden · Hôpital Xavier Arnozan1 papers (2017–2017)Zev A. Wainberg · UCLA Medical Center1 papers (2013–2013)